Perspectives

Hepatitis C and B Viruses: The New Opportunists in HIV Infection 78
Raymond T. Chung, MD
Hepatitis C Virus and HIV Coinfection • Hepatitis B Virus and HIV Coinfection

Methamphetamine Use in Urban Gay and Bisexual Populations 84
Steven Shoptaw, PhD
Physical and Psychologic Effects of Methamphetamine • Methamphetamine Use and HIV Risk • Intervention in Methamphetamine Use

Drug-Drug Interactions that Matter 88
David J. Back, PhD
Some Key Antiretroviral Drug Interactions • Is There An Alternative To Ritonavir For PI Boosting? • Other Important Interactions

Commentary

Ryan White Care Act Reauthorization: We Need Help 93
Michael S. Saag, MD
About This Issue

This issue contains 3 Perspective articles based on recent presentations at International AIDS Society–USA CME activities and conferences. At the March 2006 course in New York, NY, Raymond T. Chung, MD, discussed hepatitis B and C virus coinfections with HIV. Also at the New York conference, David J. Back, PhD, reviewed important new drug-drug interactions in HIV therapeutics. This issue also offers Steven Shoptaw, PhD’s insights about methamphetamine use among gay and bisexual men, initially delivered in February 2006 at the International AIDS Society–USA CME course in Los Angeles.

This issue also marks the start of something new — the Commentary column. In the first Commentary, International AIDS Society–USA board member Michael S. Saag, MD, has been invited to provide his observations about the Ryan White CARE Act reauthorization, healthcare funding, and the state of HIV and AIDS care delivery in the US. We welcome commentaries from other medical professionals to establish a dialogue about the disease as it moves beyond its 25th year.
Perspectives

Hepatitis C and B Viruses: The New Opportunists in HIV Infection  
Raymond T. Chung, MD  

Methamphetamine Use in Urban Gay and Bisexual Populations  
Steven Shoptaw, PhD  

Drug-Drug Interactions that Matter  
David J. Back, PhD  

Commentary

Ryan White Care Act Reauthorization: We Need Help  
Michael S. Saag, MD  

Announcements

Guidelines for Authors and Contributors  
Subscription Request  
Educational Programs of the International AIDS Society–USA
Perspective
Hepatitis C and B Viruses: The New Opportunists in HIV Infection

Coinfection with HIV accelerates disease progression in both hepatitis C virus (HCV) and hepatitis B virus (HBV) infection. Management of coinfected patients is complicated by a number of factors, including disease characteristics, drug-drug interactions, and augmented toxicity. Results of HCV and HBV treatment trials in HIV-coinfected patients and strategies for patient management are discussed herein. This article summarizes a presentation by Raymond T. Chung, MD, at the International AIDS Society–USA course in New York in March 2006.

Hepatitis C Virus and HIV Coinfection

Coinfection with HIV and hepatitis C virus (HCV) is associated with loss of immunologic control of HCV and more rapid progression of HCV disease. HIV seroconversion is associated with a dramatic increase in HCV RNA levels and HCV-specific CD8+ T-cell activity is reduced with progressive lowering of CD4+ cell counts in HIV infection (Figure 1; Kim et al, Blood, 2005). More rapid progression of liver fibrosis has been demonstrated with coinfection (Figure 2; Benhamou et al, Hepatology, 1999). Among patients with progressive HCV disease, HIV coinfection appears to markedly accelerate progression compared with HCV monoinfection; eg, reducing time to progression to cirrhosis from approximately 20 years to 10 years and time to progression to hepatocellular carcinoma, transplant, or death from approximately 25 years to 15 years. A retrospective analysis of death from end-stage liver disease among all HIV-infected patients showed an increase from rates of 10% in 1991 and 15% in 1996 to 50% in 1998 (Bica et al, Clin Infect Dis, 2001). Of those patients dying from end-stage liver disease in 1998, 55% had a plasma HIV RNA level below the limits of detection or a CD4+ cell count greater than 200/µL and all of the 91% of patients tested for HCV were HCV-seropositive.

The potential benefits of anti-HCV therapy are shared in HIV-coinfected and HCV-monoinfected patients; ie, the possibility of viral eradication, delay of progression of fibrosis, and prevention of such clinical complications as decompensation, hepatocellular carcinoma, and death. In coinfected patients, improved liver function might also improve tolerability of antiretroviral agents with hepatic adverse effects. However, anti-HCV treatment with interferon (IFN) alfa and ribavirin in HIV-coinfected patients is associated with adverse effects that can differ in type, frequency, or severity from those seen in patients without HIV infection. In HIV-coinfected patients, IFN alfa is associated with a dose-related myelosuppression (lymphocytes), flu-like symptoms, and depression. Ribavirin is associated with a dose-dependent hemolytic anemia (especially in the presence of zidovudine), teratogenicity, the potential for antagonism of zidovudine and stavudine phosphorylation, a potential increase in didanosine metabolites, and an increased risk for lactic acidosis.

Three recent trials compared pegylated IFN (peg-IFN) alfa with standard IFN alfa combined with ribavirin in patients with HIV/HCV coinfection. In the US AIDS Clinical Trials Group (ACTG) A5071 trial, biopsied patients received either peg-IFN alfa-2a 180 µg weekly plus ribavirin 600 mg/day (escalated up to 1 g/d; n=66) or IFN alfa-2a 6 mIU thrice weekly for 12 weeks and 3 mIU thrice weekly thereafter plus ribavirin at the same dose for a total of 48 weeks. Patients without virologic response were biopsied again at 24 weeks. Those with histologic...
response continued in the trial and those without response discontinued treatment. In the international APRICOT trial, patients received: (1) peg-IFN alfa-2a 180 µg weekly plus ribavirin 800 mg daily (n=289); (2) peg-IFN alfa-2a 180 µg weekly alone (n=286); or, (3) IFN–alfa-2a 3 mlU thrice weekly plus ribavirin 800 mg daily (n=285) for 48 weeks. In the French RIBAVIC trial, patients received peg-IFN alfa-2b 1.5 µg/kg/week plus ribavirin 800 mg/day (n=205) or IFN alfa-2b 3 mlU thrice weekly plus ribavirin 800 mg/day (n=207) for 48 weeks. All 3 trials assessed rates of sustained virologic response (SVR) at 72 weeks. The characteristics of the patients are listed in Table 1. Important differences include the fact that ACTG A5071 had a high proportion of African American patients; response rates in African American patients typically are markedly reduced compared with those in white patients, particularly among those with HCV genotype-1 infection. Genotype-1 infection, which is more resistant to treatment than other genotypes, was also more common in this trial. Both ACTG A5071 and the RIBAVIC trials included higher proportions of patients with bridging fibrosis or cirrhosis, factors associated with lower rates of SVR.

In ACTG A5071, SVR occurred in a significantly greater proportion of patients in the peg-IFN alfa plus ribavirin arm than in the IFN alfa plus ribavirin arm, 27% versus 12% (P = .03). SVR occurred in 14% versus 6% with genotype-1 infection and in 73% versus 53% (P < .001) with nongenotype-1 infection (Chung, *N Engl J Med*, 2004). Among virologic nonresponders, 45 of 57 in the IFN alfa plus ribavirin arm had a biopsy at 24 weeks and 16 (36%) showed histologic response. The median changes in HCV RNA were -0.61 log_{10} IU/mL in histologic responders and -0.58 log_{10} IU/mL in histologic nonresponders. Of 37 virologic nonresponders in the peg-IFN alfa group, 26 had a biopsy and 9 (35%) had a histologic response. The median changes in HCV RNA were — 1.01 log_{10} IU/mL in histologic responders and -0.71 log_{10} IU/mL in histologic nonresponders. These latter findings suggest that clinical benefit is obtained with treatment despite the absence of SVR in a sizeable proportion of patients. Among 106 patients assessed at week 12, 43 (41%) had early virologic response (a 2-log_{10} IU/mL or greater decrease in HCV RNA or conversion to HCV-seronegative status). Of these, 21 (49%) did not have SVR at 72 weeks, indicating that early response was not predictive of SVR. Of the 63 patients (59%) without early virologic response at week 12, none had SVR, indicating that absence of early response was highly predictive of absence of SVR.

In the APRICOT trial, SVR occurred in 40% of subjects in the peg-IFN alfa plus ribavirin arm, 20% of the peg-IFN alfa alone arm, and 12% of the IFN alfa plus ribavirin arm (P < .05 for each peg-IFN alfa arm vs IFN alfa arm; Torriani et al, *N Engl J Med*, 2004); SVR rates were 29% (P < .05 vs IFN alfa), 14%, and 7%, respectively, among those with genotype-1 infections, and 62% (P < .05 vs IFN alfa), 36%, and 20%, respectively, in those with nongenotype-1 infections. Figure 3 shows SVR rates by treatment and genotype. A noteworthy finding was that among patients with genotype-1 infection, those with lower HCV RNA level (≤800,000 IU/mL) had markedly greater rates of SVR than those with higher viral load (>800,000 IU/mL). In the peg-IFN alfa plus ribavirin group, SVR was observed in 61% of patients with lower HCV viral load. These find-

### Table 1. Baseline characteristics in hepatitis C virus (HCV)/HIV-coinfected patients in 3 HCV treatment studies.

<table>
<thead>
<tr>
<th>ACTG A5071</th>
<th>APRICOT</th>
<th>RIBAVIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>White/African American (%)</td>
<td>48/33</td>
<td>79/10</td>
</tr>
<tr>
<td>Genotype 1 or 4/2 or 3 (%)</td>
<td>78/22</td>
<td>68/32</td>
</tr>
<tr>
<td>Log_{10} IU/mL HCV RNA</td>
<td>6.2</td>
<td>6.7</td>
</tr>
<tr>
<td>Bridging fibrosis or cirrhosis (%)</td>
<td>44</td>
<td>16</td>
</tr>
<tr>
<td>CD4+ count (cells/µL)</td>
<td>444–492</td>
<td>520–542</td>
</tr>
<tr>
<td>Antiretroviral therapy (%)</td>
<td>86</td>
<td>84</td>
</tr>
</tbody>
</table>

ACTG indicates AIDS Clinical Trials Group.
Differences in virologic outcomes in respect, in the RIBAVIC trial. In the ACTG trial and 37% and 27%, respectively, in the APRICOT trial. In APRI- cot, the end-of-treatment (48-week) continuation rate of 31% in the RIBAVIC trials were associated with reduced response rates compared with response rates in the APRICOT trial. With regard to safety and tolerability, premature discontinuation rates were 12% in ACTG A5071 and 15% to 16% in the APRICOT trial, rates comparable to those observed in treatment trials in patients without HIV infection. The discontinuation rate of 31% in the RIBAVIC trial was at least partly due to psychiatric adverse effects, particularly depression, and hyperlactatemia, with the relative risk of the latter being extremely high in patients receiving didanosine. In all of the studies, abso-

In the RIBAVIC trial, SVR occurred in 27% of subjects in the peg-IFN alfa plus ribavirin arm versus 19% in the IFN alfa plus ribavirin arm (P < .05), including rates of 15% versus 5% (P < .05) in genotype-1 infections and 43% versus 41% in nongenotype-1 infections (Carrat et al, JAMA, 2004).

In all of the studies, peg-IFN alfa with ribavirin was significantly superior to standard IFN alfa with ribavirin in achieving SVR, and all studies showed that absence of early virologic response was highly predictive of absence of SVR. One potential difference among studies was the somewhat lower relapse rate among peg-IFN alfa patients in the APRICOT trial. In APRICOT, the end-of-treatment (48-week) virologic response rate was 47% and the SVR rate was 40%, compared with the rates of 41% and 27%, respectively, in the ACTG trial and 37% and 27%, respectively, in the RIBAVIC trial. Differences in virologic outcomes in the trials could be related to the use of the dose-escalation ribavirin in the ACTG trial versus the flat doses of ribavirin 800 mg used in the other trials. It is possible that patients in the ACTG trial were receiving too little ribavirin at the beginning of treatment, which may be a period crucial to virologic response. In addition, the greater proportion of African American patients in the ACTG trial likely had an impact on response rates in genotype-1 infections. It is also likely that the greater proportions of patients with bridging fibrosis or cirrhosis in the ACTG and RIBAVIC trials were associated with reduced response rates compared with response rates in the APRICOT trial. With regard to safety and tolerability, premature discontinuation rates were 12% in ACTG A5071 and 15% to 16% in the APRICOT trial, rates comparable to those observed in treatment trials in patients without HIV infection. The discontinuation rate of 31% in the RIBAVIC trial was at least partly due to psychiatric adverse effects, particularly depression, and hyperlactatemia, with the relative risk of the latter being extremely high in patients receiving didanosine. In all of the studies, abso-

Figure 3. Sustained virologic response (SVR) rates by treatment, hepatitis C virus (HCV) genotype, and low (L) HCV RNA level (≤ 800,000 IU/mL) or high (H) HCV RNA level (> 800,000 IU/mL) in the APRICOT trial. IFN indicates interferon, peg-IFN, peginterferon; RBV, ribavirin. Adapted from Torriani et al, N Engl J Med, 2004.

Recomendations for treating HIV/HCV coinfection are shown in Figure 4. Among patients without clinically advanced liver disease who do not yet require antiretroviral therapy or in whom HIV infection is controlled with antiretroviral therapy, the goal is to eradicate HCV using a full 48 weeks of peg-IFN alfa/ribavirin treatment. In patients with genotype-1 infection and higher HCV viral load, early discontinuation of treatment may be considered if there is no early virologic response. In patients with bridging fibrosis or cirrhosis, the goal of treatment is to delay progression. Treatment with 24 weeks of peg-IFN alfa/ribavirin or maintenance treatment should be considered. In patients with poorly controlled HIV infection and those with low CD4+ cell counts not yet receiving antiretroviral therapy, control of HIV infection is the primary objective, and anti-HCV treatment can be initiated when HIV infection is stabilized. In patients receiving antiretroviral therapy, didanosine-containing regimens should be avoided or switched, and consideration should be given to avoiding or switching zidovudine-containing regimens. Erythropoietic treatment may be considered to avoid anemia and permit optimizing of ribavirin dosing.

A mental health liaison should be in place before peg-IFN alfa treatment is initiated to assess risk for depression, and very early use of antidepressant treatment with selective serotonin...
reuptake inhibitors can be effective in stabilizing patients with symptoms of depression. Improvement of insulin resistance may improve response to anti-HCV therapy, since there are some data indicating that insulin resistance impairs sustained response to IFN alfa. Maintenance therapies are currently being evaluated in the ACTG 5178 trial. The ACTG 5184 trial is examining the effects of antiretroviral therapy on CD4+ and CD8+ T-cell response to HCV and assessing whether improvements in this regard result in improved SVR rates with peg-IFN alfa/ribavirin treatment. Patients include those with high CD4+ cell counts for whom initiation of antiretroviral therapy is not yet required according to current guidelines. Extended duration of treatment is being evaluated among patients in whom there is a failure to achieve early virologic responses.

Investigation of new agents for treating HCV continues, with promising early results being achieved with HCV protease inhibitors. One such agent, an inhibitor of the HCV NS3 serine protease, has been found to decrease HCV RNA by up to 4 log_{10} IU/mL in HCV-monoinfected patients.

Hepatitis B Virus and HIV Coinfection

The course of hepatitis B virus (HBV)-associated liver disease is also accelerated by coinfection with HIV. For example, comparison of outcomes among HIV-monoinfected, HBV-monoinfected, and HBV/HIV-coinfected patients in the Multicenter AIDS Cohort Study (MACS) reported in 2002 showed that liver-attributable mortality rates per 1000 –person-years of observation were 1.7 in HIV-seropositive patients, 0.8 in HBV surface antigen-positive (HBsAg +) patients, and 14.2 (P < .0001) in coinfected patients (Thio et al, Lancet, 2002). The relationship between coinfection and risk was strongest in the setting of low CD4+ cell count and with treatment in the post-antiretroviral therapy treatment era.

Goals of anti-HBV treatment in both mono- and coinfection consist primarily of virologic suppression, rather than clearance. All clinical improvements in the form of improved liver biochemistry, delay of cirrhosis and hepatocellular carcinoma, and reversal of histopathology, have been achieved with viral suppression alone in trials in HBV-monoinfected patients. Viral clearance in the form of conversion to HBV surface antigen-negative (HBsAg-) status, is a rare event in coinfected patients; conversion to HBV envelope antigen-negative (HBeAg-) status is rare even in HBV-monoinfected patients. Anti-HBV therapy can also be used to prevent HBV disease flares in patients with immune reconstitution syndrome after initiating antiretroviral therapy for HIV. In addition to the original standard of lamivudine monotherapy (100 mg/d po), approved therapies for HBV monoinfection include IFN alfa-2b (5 mIU sq qd or 10 mIU tiw for 16 weeks), peg-IFN alfa-2a (180 µg/week for 48 weeks), and the newer agents adefovir dipivoxil (10 mg/d po) and entecavir (0.5-1.0 mg/d po). Factors complicating HBV therapy in coinfected patients include the fact that lamivudine experience is nearly universal in this population, resulting in a very high rate of lamivudine resistance in HBV (approximately 90% by 4 years) accompanied by increases in HBV viral load. The high resistance rates also raise concerns about cross-resistance with other nucleoside analogue reverse transcriptase inhibitors (nRTIs) in this population. Durable beneficial outcomes of lamivudine monotherapy treatment are rarely observed in the coinfected population, in whom treatment of lamivudine for HIV duration is often indefinite. IFN alfa is generally poorly tolerated in the coinfected population and has limited efficacy in this setting.

The nucleotide analogues adefovir and tenofovir and the nucleoside analogue entecavir exhibit activity against both wild-type HBV and the YMDD variants resistant to lamivudine. In a study in 35 lamivudine-experienced coinfected patients, adefovir 10 mg resulted in reductions of HBV DNA of 4.68 log_{10} IU/mL at week 48, 5.24 log_{10} IU/mL at week 96, and 5.90 log_{10} IU/mL at week 144. HBeAg serocon-
version occurred in 6% of patients. Histologic improvement was observed in all 14 patients undergoing biopsy. The study dose was well tolerated; discontinuation occurred in 1 patient, due to increased serum creatinine level, with the increase resolving off treatment. A low frequency of major adefovir resistance in HBV was observed at 144 weeks; in addition, no HIV reverse transcriptase mutations were observed, a concern given the anti-HIV activity of adefovir at higher doses. These latter findings provide some hope that long-term use with this agent may be possible without prohibitive resistance (Benhamou, J Hepatol, 2006; Delaugerre et al, Antimicrob Agents Chemother, 2002). However, recent data from HBV monoinfected patients indicate that primary adefovir resistance rates increase to 18% at year 4 and to 28% at year 5 (Hadjizyannis et al, AASLD 2005).

An analysis of outcome in 10 HBV/HIV-coinfected patients showed that tenofovir 300 mg/day added to pre-existing antiretroviral therapy for HIV resulted in a 4.9 log_{10} IU/mL decrease in HBV DNA at week 24. Another analysis in 11 antiretroviral-naive coinfected patients showed that the addition of tenofovir 300 mg to the backbone of lamivudine/efavirenz produced a 4.7-log_{10} IU/mL decrease in HBV DNA at 48 weeks in 5 patients, compared with a 3.0-log_{10} IU/mL decrease and development of YMDD mutants in 4 of 6 patients in whom stavudine was combined with lamivudine/efavirenz. The ACTG 5127 trial showed that tenofovir was noninferior to adefovir in the treatment of lamivudine-resistant HBV in coinfected patients, with HBV DNA being reduced by 4.4 log_{10} IU/mL in the tenofovir group and 3.2 log_{10} IU/mL in the adefovir group. In a study in France in a coinfected population, 80% of whom had received lamivudine, tenofovir reduced HBV DNA by 4.56 log_{10} IU/mL in 52 HBeAg+ patients, with 30% having undetectable levels (<200 IU/mL), and by 2.53 log_{10} IU/mL in 13 HBeAg-patients, with 82% having undetectable levels (Dore et al, J Infect Dis, 2004; Peters et al, CROI 2005; Benhamou et al, Hepatology, 2006). Entecavir is approved for treatment of HBeAg+, HBeAg-, and lamivudine-resistant HBV infection, and has no activity against HIV reverse transcriptase. In a study in patients with HBV monoinfection, entecavir 0.5 mg reduced HBV DNA by 6.98 log_{10} IU/mL at 48 weeks, compared with a 5.48-log_{10} IU/mL reduction with lamivudine 100 mg. In a randomized trial in lamivudine-experienced coinfect patients, the addition of entecavir 1.0 mg to lamivudine produced a 3.66 log_{10} IU/mL decrease in HBV DNA at week 24 compared with no change in patients with placebo added to lamivudine. There is a lower threshold for entecavir resistance in patients with pre-existing lamivudine resistance; in the current study, mutations associated with entecavir resistance were found in 2 (4%) of 48 patients but no phenotypic evidence of resistance was observed at 48 weeks (Pessoa et al, CROI, 2005; Colonnro et al, CROI, 2006. See also Chang et al, N Engl J Med, 2006 and Lai et al, N Engl J Med, 2006).

Management of HBV/HIV coinfection should include assessment of HBV status in all patients prior to the initiation of antiretroviral therapy for HIV. For patients on antiretroviral therapy for HIV that includes lamivudine, a reasonable approach is the addition of entecavir for HIV and who have replicative HBV, institution of antiretroviral therapy containing tenofovir plus lamivudine or entecitabine is a recommended approach to provide coverage for both HIV and HBV. For those in whom antiretroviral therapy for HIV can be deferred, use of agents without crossover anti-HIV activity or that pose less risk for the emergence of HIV resistance is preferable, with adefovir 10 mg and entecavir 1 mg being reasonable choices. Development of effective combination therapies will be necessary to minimize development of resistance during longer-term therapy.


Financial Disclosure: Dr Chung has received grants and research support from Roche and Schering.

Suggested Reading


Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients co-


*Top HIV Med.* 2006;14 (2):78-83

Copyright 2006, International AIDS Society–USA
Perspective

Methamphetamine Use in Urban Gay and Bisexual Populations

It is estimated that the use of methamphetamine is 5- to 10-times more common in urban gay and bisexual men than in the general US population. Given its effects in stimulating energy, confidence, and libido, as well as its relative inexpensiveness, the drug can efficiently address serious problems in functioning among HIV-infected men, who may suffer significant symptoms of depression or fatigue associated with chronic illness and HIV-related drug treatments. Long-term methamphetamine use is associated with physical, psychologic, and social adverse effects. Increased use of the drug associates with more frequent sexual risk behaviors and increased risks for HIV transmission. Behavioral therapies, notably the approach of contingency management, are being investigated for reducing methamphetamine use and risk behaviors in the urban gay population. This article summarizes a presentation made by Steven Shoptaw, PhD, at the International AIDS Society–USA course in Los Angeles in February, 2006.

Methamphetamine is a long-acting stimulant. It goes by various street names, including crystal, tina, speed, and crank. It can be injected, insufflated (snorted), smoked (eg, by heating on aluminum foil and inhaling the vapor through a pen or straw), taken orally, or taken via “booty-bump” (anal insertion). Methamphetamine comes in forms that can range from a powder that can be white, yellow, orange, pink, or brown (depending on the chemicals used in processing and the expertise of the “cook”) to an “ice” form consisting of high-purity methamphetamine crystals or coarse powder that is translucent to white, sometimes with a green, blue, or pink tinge. In general, the purity of methamphetamine on the street is very high, with coloring having little to do with potency of the drug.

Methamphetamine has a half-life of 9 to 12 hours, is inexpensive (approximately $25–$50 per gram), and is used by many different groups, including gay and bisexual men, blue-collar heterosexuals, and youth. There is an especially high prevalence of use in urban gay and bisexual men, estimated at 5- to 10-times that in the general population. Data from San Francisco and Los Angeles indicate methamphetamine use within the prior 6 months in 13% and 11%, respectively, of gay men (Stall et al, Addiction, 2001).

Physical and Psychologic Effects of Methamphetamine

Acute physical and psychologic effects and chronic physical effects of methamphetamine use are listed in Table 1. Medical complications associated with use include: tachycardia, hypertension, tachypnea, hyperthermia, and central nervous system (CNS) excitation; rhabdomyolysis and cardiovascular events, including myocardial infarction and stroke, especially in young patients (29–45 years of age); impairment of CD8+ T-lymphocyte function; and acute pulmonary hypertension associated with smoking the drug. Methamphetamine use is also associated with “meth mouth;” this rotting of the teeth around the gums is related to neglect, xerostomia, decreased fluid intake and intake of high-sugar drinks, characteristics of the drug itself that result in shrinking of the gingival tissue, and bruxism.

Methamphetamine use in gay men is rarely casual, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for dependence or abuse should be applied to determine the extent of the use problem once it is identified (Table 2). The acute physical effects are listed in Table 1.

Table 1. Acute Physical and Psychologic Effects and Chronic Physical Effects of Methamphetamine Use (see Peck et al, J Addict Dis, 2005).

<table>
<thead>
<tr>
<th>Acute physical effects</th>
<th>Increases</th>
<th>Decreases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pupil size</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensory acuity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appetite</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reaction time</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute psychologic effects</th>
<th>Increases</th>
<th>Decreases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confidence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alertness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex drive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Talkativeness</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chronic physical effects</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight loss</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinus infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweating</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burned lips; sore nose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oily skin/complexion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headaches</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dr Shoptaw is a Professor in the Department of Family Medicine at the University of California, Los Angeles.
amphetamine (MDMA, or ecstasy) by 3- to 3,4-methylenedioxy-N-methylam- 

Levels of both methamphetamine and CYP2D6 and has been shown to increase via CYP3A4, but ritonavir also affects 

Street PIs generally are metabolized 

The effect of the HIV protease inhibitor (PI) 

The nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) 

Delavirdine also is partially metabolized 

Reverse transcriptase inhibitor (NNRTI) 

All have occurred in patients taking 

The risk of metham-

phentamine toxicity is increased in the approximately 3% to 10% of the white population that has a polymorphism in 

The cytochrome P450 (CYP) 2D6 isoenzyme. It needs to be emphasized that the effect of the HIV protease inhibitor (PI) ritonavir on prolonging the methamphetamine high is well recognized on the street. PIs generally are metabolized via CYP3A4, but ritonavir also affects 

And has been shown to increase levels of both methamphetamine and 3,4-methylenedioxy-N-methyamph- 

Methamphetamine use also frequently 

In particular, among individuals who may be wrestling with the consequences of having a chronic illness such as HIV disease and who may therefore be socially withdrawn or depressed, or those who are suffering from drug treatment-related fatigue or other adverse effects of HIV drug therapy. However, there is often a high price exacted for these "benefits." In addition to the chronic physical effects and complications noted above, the dangers of use include significant risk for psychosis (risk that may persist for years after drug use has stopped), depression, violence, family and social disruptions, and criminal activity. Among men who have sex with men (MSM), methamphetamine abuse increases the likelihood of infection with HIV, in those infected with HIV, it may exacerbate neurotoxicity and other pathologic processes common to HIV infection and complicate the treatment of infection. Methamphetamine use, HIV infection, and HCV infection are each associated with neuropsychologic functioning deficits, with additive deficits being found when the conditions are present together. Methamphetamine use also frequently occurs in tandem with the use of poppers (amyl nitrite), which has been independently implicated as a risk factor for transmission of sexually transmitted infections, such as HIV (including resistant virus) and HCV.

Methamphetamine is metabolized by 

10-fold. A few overdose deaths have been reported in HIV-infected patients using methamphetamine or MDMA, and all have occurred in patients taking 

The nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) 

Delavirdine also is partially metabolized 

Via CYP2D6, and would be expected to 

Slow metabolism of methamphetamine 

And MDMA. The risk of metham-

Phentamine toxicity is increased in the 

Approximately 3% to 10% of the white 

Population that has a polymorphism in 

The CYP2D6 gene.

Methamphetamine Use and HIV Risk

Data on methamphetamine use and prevalence of HIV infection among gay men suggest a time-to-response phenomenon, in which the longer or more heavily involved individuals are in using methamphetamine, the more likely they are to be HIV infected. As shown in Figure 1, a study in the Los Angeles area shows that the prevalence of HIV infection increases in a stepwise fashion from approximately 10% in occasional methamphetamine users, to more than 20% of regular users, more than 40% of chronic users, 60% of men in outpatient drug-free treatment, and 86% of men in a gay-specific social model recovery house (Reback, Report from the City of Los Angeles, AIDS Coordinator, 1997, Shoptaw et al, Drug Alcohol Depend, 2005). The increased risk of HIV infection with methamphetamine use is attributable to increased sexual risk behaviors. Some idea of the sexual disinhibition associated with methamphetamine use is provided by a study in a population of methamphetamine-abusing heterosexual men and women in San Diego (Semple et al, Addict Behav, 2004). In this population, the average number of episodes of vaginal sex within the past 30 days was 20, compared with a national average of 6 to 7 in the general population, and the average number of sex partners in the past 60 days was 11, compared with 1 to 2 in the general population.

Project EXPLOR.E in San Francisco found that at baseline among 736 initially HIV-seronegative gay men followed up for risk behaviors, approximately 35% had used poppers, approximately 20% cocaine, and approximately 25% methamphetamine within the prior 60 days (Colfax et al, Curr HIV/AIDS, 2005). Logistic regression analysis among 386
participants, yielded odds ratios (ORs) for HIV-serodiscordant unprotected anal sex of 1.5 (95% confidence interval [CI], 1.1–1.9) for those using 1 of these drugs less than 1 week out of the month, 2.2 (CI, 2.2–4.7) for 2 drugs less than 1 week out of the month, 2.8 (CI, 1.6–4.9) for 3 drugs less than 1 week in the month, and 2.2 (CI, 1.5–3.4) for at least 1 drug used weekly. In a treatment study in methamphetamine-abusing MSM in Los Angeles, significant univariate predictors of HIV-seropositive status included prior treatment for methamphetamine use (OR, 4.3; \( P = .0006 \)), as well as unprotected receptive anal intercourse (OR, 3.5; \( P = .0046 \)), history of sexually transmitted diseases (OR, 1.5; \( P = .0047 \)), suicidal or homicidal ideation at admission (OR, 6.5; \( P = .0057 \)), and positive health insurance status (OR, 3.0; \( P = .0060 \); Peck et al, Addict Dis, 2005).

**Intervention in Methamphetamine Use**

Given the high prevalence of methamphetamine use in urban gay men, any clinical practice in such a setting should establish a routine for assessing methamphetamine use. Use of the 5 “A”s—Ask, Assess, Advise, Assist, and Arrange—is part of good practice in helping patients to stop any kind of substance abuse. For methamphetamine use, in particular, it is useful to ask all patients in such a setting the question: “How much methamphetamine have you used since your last visit?” Behavioral treatments can have a dramatic effect on methamphetamine use (Shoptaw et al, Drug Alcohol Depend, 2005). One such treatment is that of contingency management, a behavioral therapy that shapes behavior change by the provision of immediate reinforcements when the desired behavior is produced. Contingency management strategies validated for use with stimulant abusers typically provide vouchers of increasing value for provision of successive methamphetamine-free urine samples. Vouchers are then exchanged for goods or services that promote a drug-free lifestyle (see Higgins et al, Am J Psychiatry, 1993). In an intervention study of 162 treatment-seeking methamphetamine-abusing gay men, contingency management resulted in significantly longer retention in treatment, significantly more drug-free urine samples, and significantly longer stretches of consecutive clean urine samples (Shoptaw et al, Drug Alcohol Depend, 2005). This study also showed that provision of this and other behavioral drug-abuse treatments resulted in prompt and sustained reductions in unprotected receptive and insertive anal intercourse (Figure 2). This type of sustained risk reduction is a rare finding in HIV prevention trials. Based on these results, contingency management was adopted into a San Francisco public health initiative called Positive Reinforcement Opportunity Project in an attempt to extend these benefits into the methamphetamine-abusing population not actively seeking drug-abuse treatment. The program permitted access to the intervention in nontraditional settings and, in effect, allowed individuals who were not necessarily interested in seeking help to nevertheless be linked into treatment. The program found that contingency management helped about half of MSM to reduce or eliminate methamphetamine use.

Currently, there are no effective pharmacologic methods available for treating methamphetamine abuse. Modafinil is a nonamphetamine-type stimulant that has shown some promise in treating fatigue in HIV-infected individuals. The drug has some favorable characteristics, including promoting wakefulness (it is currently approved for treating narcolepsy), improving cognitive function, and being only a mild inducer of CYP; it is a schedule IV drug with what is believed to be a low abuse potential. In a small study in HIV-infected individuals, modafinil reduced fatigue, reduced depression, and improved neuropsychologic functioning (memory, speed of processing, and executive function) and was associated with only mild side effects (Rabkin et al, J Clin Psychiatry, 2004). The National Institute on Drug Abuse is interested in assessing this drug as a treatment for methamphetamine abuse in HIV-seropositive patients, and is currently performing a phase II trial of the drug in patients with cocaine dependence. It would also be reasonable to evaluate the drug in the treatment of methamphetamine abuse in HIV-seronegative individuals. Other potential candidates for treating methamphetamine abuse
include bupropion, which showed borderline effectiveness in reducing methamphetamine use in a recent phase II trial (Elkashef, The Methamphetamine Menace, 2005).

**Summary**

Methamphetamine use is very common in urban populations of MSM, and increased use is associated with increased risks of numerous adverse health consequences and increased prevalence of sexual risk behaviors for HIV transmission. Methamphetamine is a highly functional drug in this population, producing increased energy, confidence, and libido; for those with HIV infection, it helps the individual to temporarily forget about HIV infection, to feel powerful and attractive in his body and to reduce fatigue associated with chronic illness and HIV medications. Given the high prevalence of methamphetamine use among MSM, it is wise to screen all gay and bisexual patients in care settings for methamphetamine use.

At the very least, each contact with MSM should contain a brief intervention that includes a strongly worded message about the need to not start or to discontinue methamphetamine use that includes support and information for not starting or for quitting. Behavioral interventions, including contingency management, are successful in producing sustained reduction in methamphetamine use and HIV risk behaviors (Shoptaw et al, Drug Alcohol Depend, 2005). Investigation is underway to identify drug treatments that may help in reducing methamphetamine use.

**Perspective – Methamphetamine Use**

**Figure 2.** Sustained reduction in unprotected anal receptive intercourse among men who have sex with men receiving treatment for methamphetamine abuse. CBT indicates cognitive behavioral therapy; CM, contingency management; GCBT, group CBT. $\chi^2(3)=6.75$; $P<.01$. Adapted from Shoptaw et al, Drug Alcohol Depend, 2005.

include bupropion, which showed borderline effectiveness in reducing methamphetamine use in a recent phase II trial (Elkashef, The Methamphetamine Menace, 2005).

**Summary**

Methamphetamine use is very common in urban populations of MSM, and increased use is associated with increased risks of numerous adverse health consequences and increased prevalence of sexual risk behaviors for HIV transmission. Methamphetamine is a highly functional drug in this population, producing increased energy, confidence, and libido; for those with HIV infection, it helps the individual to temporarily forget about HIV infection, to feel powerful and attractive in his body and to reduce fatigue associated with chronic illness and HIV medications. Given the high prevalence of methamphetamine use among MSM, it is wise to screen all gay and bisexual patients in care settings for methamphetamine use at each clinic visit. At the very least, each contact with MSM should contain a brief intervention that includes a strongly worded message about the need to not start or to discontinue methamphetamine use that includes support and information for not starting or for quitting. Behavioral interventions, including contingency management, are successful in producing sustained reduction in methamphetamine use and HIV risk behaviors (Shoptaw et al, Drug Alcohol Depend, 2005). Investigation is underway to identify drug treatments that may help in reducing methamphetamine use.

**Presented in February 2006. First draft prepared from transcripts by Matthew Stenger. Reviewed and updated by Dr Shoptaw in April 2006.**

**Financial Disclosure:** Dr Shoptaw has no affiliations with commercial organizations that may have interests related to the content of this article.

**Suggested Reading**


**Perspective**

**Drug-Drug Interactions that Matter**

It is increasingly difficult to keep track of information on drug-drug interactions in HIV therapeutics, and the clinical implications of much of the data reported are not immediately evident. Nevertheless, knowledge of drug-drug interactions is necessary to preserve antiretroviral efficacy and to avoid undue risk of toxicity. The following article reviews important drug-drug interactions and accumulating data on newer antiretroviral agents. The article summarizes a presentation made by David J. Back, PhD, at the International AIDS Society–USA course in New York in March 2006.

Data on drug-drug interactions in HIV therapeutics continue to accumulate at a rapid pace. The clinical significance of such information, however, is not always clear. Some of the reported information is contradictory or counterintuitive. Further, it is not always easy to determine whether interactions affect the balance between antiretroviral activity and the risk for drug-related adverse effects. The matter is also complicated by the wide interindividual variability in drug pharmacokinetics; differences between individual patients can depend on such factors as genetic differences, sex, inherent variability in drug formulations, drug-food interactions, and drug-disease interactions. Despite the complexities, potential drug interactions must be considered when starting or changing anti-retroviral therapy. In general, medications with the lowest potential for interactions should be selected for use. Good resources on HIV pharmacology include the following Web sites: www.hivdruginteractions.org; www.hivpharmacology.com; www.tthhivclinic.com; http://hivinsite.ucsf.edu; www.hivinsight.com; and http://clinicaloptions.com.

**Some Key Antiretroviral Drug Interactions**

Some key interactions of protease inhibitors (PIs) with other PIs or nonnucleoside analogue reverse transcriptase inhibitors (NNRTIs) are shown in Table 1. As shown, the combination of tipranavir and lopinavir is not recommended due to a marked decrease in lopinavir exposure.

However, a recent small study examined whether increasing lopinavir doses might overcome this effect (Harris et al, CROI, 2006). In this study, 13 HIV-infected patients receiving ritonavir-boosted (r) lopinavir 400 mg/100 mg twice daily and no other PIs or NNRTIs were given tipranavir 500 mg twice daily and either (1) lopinavir/r 400 mg/500 mg twice daily or (2) lopinavir/r 533 mg/233 mg twice daily. At 14 days, neither group had lopinavir trough concentrations different from those prior to the addition of tipranavir and dose changes; however, there was marked interpatient variability in these concentrations (Figure 1). Such findings suggest that the combination should be considered only if TDM is used to guide dosing in individual patients.

In fact, tipranavir/r is likely to have a somewhat complicated interaction profile because it affects levels of other drugs via more than 1 mechanism. With concomitantly coadministered PIs, the effect of tipranavir/r is likely mediated to a large extent by an inducing effect on P-glycoprotein and possibly other transporter molecules. With other drugs, the net in vivo effect of tipranavir/r is inhibition of cytochrome P450 (CYP) 3A4, as a result of ritonavir inhibiting this enzyme (ie, the inhibition by ritonavir is greater than

### Table 1. Selected Key Protease Inhibitor-Protease Inhibitor and Protease Inhibitor-Nonnucleoside Analogue Reverse Transcriptase Inhibitor Interactions

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Drug Concentration</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/r + Saquinavir</td>
<td>Lopinavir ↔</td>
<td>Saquinavir ↔</td>
</tr>
<tr>
<td>Lopinavir/r + Fosamprenavir</td>
<td>Lopinavir ↓</td>
<td>Fosamprenavir ↓</td>
</tr>
<tr>
<td>Lopinavir/r + Indinavir</td>
<td>Lopinavir ↔</td>
<td>Indinavir ↔</td>
</tr>
<tr>
<td>Lopinavir/r + Atazanavir</td>
<td>Lopinavir ↔</td>
<td>Atazanavir ↔</td>
</tr>
<tr>
<td>Saquinavir/r + Atazanavir</td>
<td>Saquinavir ↑</td>
<td>Atazanavir ↔</td>
</tr>
<tr>
<td>Saquinavir/r + Fosamprenavir</td>
<td>Saquinavir ↓</td>
<td>Fosamprenavir ↔</td>
</tr>
<tr>
<td>Tipranavir/r + Lopinavir, Saquinavir, Amprenavir</td>
<td>Lopinavir, Saquinavir, Amprenavir ↓</td>
<td>Tipranavir ↔</td>
</tr>
<tr>
<td>Lopinavir/r + Nevirapine</td>
<td>Lopinavir ↓</td>
<td>Nevirapine ↔</td>
</tr>
<tr>
<td>Lopinavir/r +Efavirenz</td>
<td>Lopinavir ↓</td>
<td>Efavirenz ↔</td>
</tr>
<tr>
<td>Saquinavir/r + Efavirenz</td>
<td>Saquinavir ↔</td>
<td>Efavirenz ↔</td>
</tr>
<tr>
<td>Atazanavir/r + Efavirenz</td>
<td>Atazanavir ↓</td>
<td>Efavirenz ↔</td>
</tr>
</tbody>
</table>

C indicates combination not recommended; D, dose adjustment needed; N, no clinically relevant interactions; r, low-dose ritonavir

Data in table compiled from multiple published sources. For full information please refer to the author’s drug interaction web site www.hiv-druginteractions.org.

---

Dr Back is a Professor of Pharmacology at the University of Liverpool.
the effect of tipranavir. As an inhibitor of CYP3A4, tipranavir/r increases rifabutin area under the concentration-time curve (AUC) 2.9-fold, increases the AUC of the rifabutin active metabolite 20-fold, and increases atorvastatin AUC 9-fold (van Heeswijk, ICAAC, 2004; van Heeswijk et al, International Workshop on Clinical Pharmacology in HIV Therapy, 2004). Given the numerous potential drug interactions with tipranavir/r, it should be used with caution when its potential effects in combination are not known.

Effects of tipranavir/r and other boosted PIs on AUCs of other commonly used drugs are shown in Table 2; similar effects among the PIs are highlighted. Differences include the effects of acid-reducing agents on the levels of PIs. It is of interest that the increased AUC of the nucleotide analogue reverse transcriptase inhibitor (nRTI) tenofovir with boosted PIs was an unexpected effect, with the mechanism remaining unclear. Increases in tenofovir AUC or trough concentrations have been observed with saquinavir/r and the PI darunavir (TMC 114; approved by the US Food and Drug Administration in June 2006/r), but fosamprenavir/r does not appear to affect tenofovir trough levels. The clinical relevance of the increase in tenofovir exposure, and of the apparent differences in effect in this regard among PIs, also remains unclear.

In relation to combinations of tipranavir/r with NNRTIs, available data indicate no significant interactions with efavirenz or nevirapine. However, a recent study of tipranavir/r in combination with the investigational NNRTI etravirine (TMC125) in volunteers showed that etravirine exposure was reduced by 76% and tipranavir and ritonavir exposures were increased by 18% and 23%, respectively (Scholler et al, CROI, 2006). These findings suggest that etravirine and tipranavir/r should not be used together.

With regard to some newer agents, the PI darunavir does not appear to have clinically relevant interactions with atazanavir, tenofovir, omeprazole, or ranitidine, but does exhibit a significant interaction with atorvastatin that requires dose modification. (See Table 3.) A study of darunavir and etravirine in combination in HIV-infected subjects with 3-class antiretroviral drug resistance showed no significant pharmacokinetic interaction between the 2 (Boffito et al, CROI, 2006). The investigational CCR5 antagonist maraviroc (UK427,857) is metabolized via CYP3A4. The maraviroc AUC is increased 4.9-fold with atazanavir/r (3.6-fold with atazanavir), 5.8-fold with lopinavir/r, 2.5-fold with lopinavir/r plus efavirenz, 8.3-fold with saquinavir/r (4.3-fold with saquinavir), 5-fold with saquinavir/r plus efavirenz, 2.6-fold with ritonavir, and 5-fold with ketoconazole. The maraviroc AUC is increased 4.9-fold with atazanavir/r (3.6-fold with atazanavir), 5.8-fold with lopinavir/r, 2.5-fold with lopinavir/r plus efavirenz, 8.3-fold with saquinavir/r (4.3-fold with saquinavir), 5-fold with saquinavir/r plus efavirenz, 2.6-fold with ritonavir, and 5-fold with ketoconazole. The maraviroc AUC is increased 4.9-fold with atazanavir/r (3.6-fold with atazanavir), 5.8-fold with lopinavir/r, 2.5-fold with lopinavir/r plus efavirenz, 8.3-fold with saquinavir/r (4.3-fold with saquinavir), 5-fold with saquinavir/r plus efavirenz, 2.6-fold with ritonavir, and 5-fold with ketoconazole. The maraviroc AUC is
decreased by 50% with efavirenz alone and by 70% with rifampicin. No change in maraviroc exposure has been observed with coadministration with nevirapine or tipranavir.

**Is There An Alternative To Ritonavir For PI Boosting?**

None of the other drugs that have been examined as potential PI boosters provides the same magnitude of effect as ritonavir (Table 4). The potential for atazanavir boosting of saquinavir was recently assessed in a crossover trial in which healthy subjects received twice-daily saquinavir 1000 mg/100 mg, saquinavir/atazanavir 1000 mg/200 mg, or saquinavir/atazanavir 1500 mg/200 mg (King et al, CROI, 2006). Saquinavir concentrations over 12 hours following dosing on day 10 were markedly higher with ritonavir 100 mg than with atazanavir boosting (Figure 2); it was also found that saquinavir concentrations at the higher atazanavir-boosted saquinavir dose were lower than those at the lower atazanavir-boosted saquinavir dose. Another recently reported crossover trial assessed atazanavir 400 mg, fosamprenavir 1400 mg, and the combination in 21 HIV-seronegative subjects (Clay et al, CROI, 2006). When the drugs were given alone, AUCs were 17.9 µg.h/mL and 21.7 µg.h/mL for atazanavir and amprenavir, respectively, compared with 11.9 µg.h/mL (33% decrease) for atazanavir and 38 µg.h/mL (78% increase) for amprenavir when the drugs were given together. Combined treatment decreased atazanavir minimum concentrations by 0.06 µg/mL to 0.14 µg/mL and increased amprenavir minimum concentrations by 0.06 µg/mL to 0.23 µg/mL.

**Other Important Interactions**

**Acid-Reducing Agents**

Interactions between acid-reducing agents (ARAs) and PIs are shown in Table 5. It should be noted that there may be differences in potency among agents within each class of ARA that can result in different magnitudes of effect on PI exposure. Concomitant use of proton pump inhibitors and indinavir should be avoided. There are data suggesting that concomitant use of atazanavir and H2 blockers is possible if dosing of the 2 agents is separated by 10 hours. The clinical significance of decreased tipranavir exposure, decreased fosamprenavir exposure, and increased saquinavir exposure with concomitant ARA use currently is uncertain. Further information on ARA interactions with antiretroviral drugs is needed, with attention given to coadministration versus staggered administration, interactions in HIV-infected patients (in addition to HIV-uninfected subjects), effects of different dose levels of individual ARAs, and potential clinical consequences of any identified pharmacokinetic interactions.

**Fluticasone**

The potent locally-acting glucocorticoid fluticasone is rapidly metabolized via CYP3A4 after oral dosing. Coadministration with ritonavir or other CYP3A4 inhibitors, however, raises the potential for markedly increased systemic exposure and a marked decrease in endogenous cortisol levels. Consequences can include systemic effects such as adrenal sup-

---

**Table 4. Effects of Various Boosting Agents on Saquinavir, Amprenavir, and Indinavir**

<table>
<thead>
<tr>
<th>Boosting Agent</th>
<th>Saquinavir</th>
<th>Amprenavir</th>
<th>Indinavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>120%↑</td>
<td>ND</td>
<td>←</td>
</tr>
<tr>
<td>Grapefruit juice</td>
<td>50%↑</td>
<td>←</td>
<td>←</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>70%↑</td>
<td>31%↑</td>
<td>62%↑</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>28%↑</td>
<td>ND</td>
<td>←</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>50%↑</td>
<td>ND</td>
<td>25%↓</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>187%↑</td>
<td>18%↑</td>
<td>20%↑</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>100%↑</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Delavirdine</td>
<td>120%↑</td>
<td>300%↑</td>
<td>70%↑</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>*</td>
<td>80%</td>
<td>ND</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>400%-1000%↑</td>
<td>100%-200%↑</td>
<td>270%-400%↑</td>
</tr>
</tbody>
</table>

*Atazanavir 400 mg gives up to 50% of the boost given by ritonavir 100 mg. ND indicates no data.

Data in table compiled from multiple published sources. For full information please refer to the author's drug interaction web site www.hiv-druginteractions.org.
Table 5. Effects of Acid-Reducing Agents on Protease Inhibitors

<table>
<thead>
<tr>
<th>Protease Inhibitor</th>
<th>Antacids</th>
<th>H2 Blockers</th>
<th>Proton Pump Inhibitors</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saquinavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1000/100 mg bid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indinavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(800 mg tid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(400 mg/100 mg bid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosamprenavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1400 mg bid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(700 mg/100 mg bid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(400 mg qd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(300 mg /100 mg qd)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tipranavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(500mg/200mg bid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/r</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(400 mg/100 mg bid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AUC indicates area under the concentration-time curve; bid, twice daily; C12, concentration at end of 12-hour dosing interval; H2 blocker, histamine H2 receptor antagonist; Cmin, minimum concentration; qd, daily; tid, thrice daily. Data in table compiled from multiple published sources. For full information please refer to the author’s drug interaction web site www.hiv-druginteractions.org.

Table 6. Interactions Between Antiretroviral Drugs and Methadone or Buprenorphine

<table>
<thead>
<tr>
<th>Methadone Buprenorphine</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Atazanavir</td>
<td>?↑</td>
</tr>
<tr>
<td>Fosamprenavir</td>
<td>13% ↓</td>
</tr>
<tr>
<td>Indinavir</td>
<td>?↑</td>
</tr>
<tr>
<td>Lopinavir/r</td>
<td>30%-50% ↓</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>47%↓</td>
</tr>
<tr>
<td>Saquinavir</td>
<td>32%↓</td>
</tr>
<tr>
<td>Tipranavir</td>
<td>50%↓</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>52%↓</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>46%↓</td>
</tr>
</tbody>
</table>

Data in table compiled from multiple published sources. For full information please refer to the author’s drug interaction web site www.hiv-druginteractions.org.

Methadone and Buprenorphine

As listed in Table 6, available data indicate that most PIs and the NNRTIs efavirenz and nevirapine reduce morphine levels. Although there are few substantive data in this regard, buprenorphine levels are believed to be increased by PIs and reduced by efavirenz and nevirapine.

CYP Genomics

Differences in genes regulating CYP enzymes can have significant effects on drug metabolism and exposure. For example, 1 study of polymorphisms at the 516 position of the CYP2B6 gene has shown that individuals with the 516T/T variant have a 3-fold increase in efavirenz concentrations and markedly increased efavirenz AUC compared with individuals with wild-type 516G/G or the 516T/G variant (Haas et al, AIDS, 2004). Data from a study in the Swiss HIV Cohort indicate that most patients with very high efavirenz concentrations on standard doses, some of whom had central nervous system (CNS)-related toxicity, had single nucleotide polymorphisms in the CYP2B6 gene at both the 516 and 785 positions. In the case of efavirenz, and other drugs for which pharmacogenomic data are accumulating, it is unclear at present whether genotypic testing or TDM should be used to guide dosing. It is likely that most genotypic and phenotypic relationships affecting drug metabolism and exposure reflect the involvement of numerous genes and numerous polymorphisms. As more information in this regard is gained, genotypic testing is likely to be an increasingly used tool in both selecting antiretroviral agents and achieving optimal dosing.

Presented by Dr Back in March 2006. First draft prepared from transcripts by Matthew Stenger. Reviewed and updated by Dr Back in June 2006.

Suggested Reading


King J, Paul Lundy S, Kakuda T, Becker S, Acosta E. Pharmacokinetics of saquinavir with low-dose ritonavir or atazanavir twice daily in seronegative volunteers: ASPIRE II.


Copyright 2006, International AIDS Society–USA
Commentary
Ryan White Care Act Reauthorization: We Need Help

In this, the first Commentary column for Topics in HIV Medicine, Michael S. Saag, MD, has been invited to share his insights and observations about reauthorization of the Ryan White CARE Act, the healthcare funding crisis, and the changing nature of HIV and AIDS care delivery in the US. His opinion piece heralds a new approach for this publication, which welcomes commentaries on other medical and social issues arising from an epidemic in transition.

The University of Alabama at Birmingham (UAB) 1917 Clinic is the largest HIV/AIDS clinic in Alabama and one of the largest in the Southeast United States. If it is a ship, it is sinking. If it is a fortress, the walls are breached and falling. If it is a haven, it is burning. We know we are not alone in this failure. Many HIV/AIDS private practices are closing and public clinics across the country are absorbing the additional burdens of care. We are losing devoted and resourceful HIV/AIDS healthcare personnel, who are flaming out while using ridiculously insufficient resources to meet impossible and increasing demands. We need help. Some of this help can come through appropriate reauthorization of the Ryan White CARE Act (RWCA).

The Ryan White CARE Act was created in 1990 with the intent of helping both individual HIV/AIDS patients and a healthcare system stunned by the demands of caring for the growing numbers of these patients. In those early days, we had few therapeutic options and a poorer understanding of the disease. Mostly, we battled opportunistic illnesses and helped patients die with dignity. Political mobilization within the gay community created political and public awareness of the disease and was critical in mounting and maintaining community-based prevention and treatment efforts. This made work for us in the medical community somewhat easier, since a large proportion of our patient population was self-organized and active in seeking responsive legislation and healthcare.

Over the decade and a half since the CARE Act was first authorized, the nature of the epidemic in the US has changed in a number of important ways. Most importantly, owing to the breathtaking success of prior research and treatment efforts—patients are living. With the advent of potent antiretroviral therapy and improved understanding of the disease, patients are living far longer lives. This gain, however, is not the result of drugs alone; it occurs in the context of successful efforts at timely diagnosis, effective counseling, improved monitoring for viral resistance and virologic response, and skilled management of therapies to address toxicities and resistance—that is, improved overall care. Our patients can now live, they can work and be productive again, but they still require careful vigilance and provision of complex medical care. Narrow focus on increased funding to improve access to drugs is misguided; the primary emphasis should be on providing access to care. Without provision of appropriately sophisticated care the drugs will not be effective and resistant virus will become rampant. Stated another way, what good are drugs if they are not used properly?

Another change is the ongoing shift of growth of the epidemic to disadvantaged populations; the population in which the epidemic is growing fastest is largely poor and underinsured or uninsured and has virtually no political organization or advocacy. These patients typically present with advanced disease, having missed the chance for early diagnosis, timely treatment, and prevention counseling. Patients diagnosed later in the course of disease (CD4+ counts <200 cells/µL) have a substantially higher degree of HIV-related morbidity and mortality. In addition, they have spent greater amounts of time at risk for transmitting disease. It also costs more to treat sicker patients. Studies at UAB have shown that annual costs for patients initiating antiretroviral therapy at CD4+ cell counts below 200 cells/µL, who now constitute more than 70% of our patient population, are significantly higher than for those diagnosed with higher CD4+ counts. For the 33% of patients in our clinic who present initially with CD4+ counts below 50 cells/µL, their costs are 2 to 5 times greater than costs in patients diagnosed with more than 50 cells/µL. Of note, medications are mostly responsible for the increases in these costs. Seventy-eight percent of costs were due to medications and not to hospitalization (7%) as might be anticipated. Most of the medication costs in the below 50 CD4+ cells/mL group were due to non-antiretroviral costs; the costs for antiretroviral medications remained constant across all CD4+ strata.

What is most striking in this cost analysis is that payment for physician services represents less than 2% of total expenditures, or $360 per patient per year. This value assumed that all patients were insured and the collection rate was 100%. In our clinic of 1250 patients, this degree of reimbursement would yield a total of $450,000. However, typically, 30% of our patients have no insurance and our collection rate is about 45%—yielding annual collection from fee for services of around $250,000. Collections for provision of infusion therapy average $240,000 per year. RWCA Title III provided us with $508,000 for 2005. Together, these sources contribute less than $1,000,000 to our overall budget of $2.4 million, with UAB making up the remainder.

Taken together, the current level of funding through RWCA is inadequate to cover the costs of care for patients in 2006. Although most HIV clinics and practices, including ours, have had a 40% to 60% increase in patient volume over the past 5 years, our RWCA funding has been flat for the
past 7 years, with RWCA Title III clinics actually suffering a 2.5% funding reduction in early 2006. And, of course, it gets worse. In 2005, the proportion of new patients referred to the UAB clinic with no insurance whatsoever increased to 46%, in what is likely to be a trend. Staffing has been flat for 5 years despite a 50% increase in patient census. In addition, our social workers now spend 95% of their time exclusively accessing medications for patients, including monitoring compassionate use program eligibility or renewals, performing Medicare plan D counseling, and completing applications and tracking waiting lists for the AIDS Drug Assistance Program (ADAP). Our nurses also spend substantial amounts of their time serving as advocates for medicine access—that is handling prior authorizations and the numerous Medicare Plan D complications, including multiple plans with different rules, multiple formularies, rejection of prescriptions, long forms and long wait times to talk with insurance providers, and absence of means to track prior authorization requests. ADAP itself has spurred a sub-industry at our clinic. None of the more than 200 patients currently on the ADAP waiting list for medications has gone without treatment. Rather, we apply to compassionate use programs of the pharmaceutical companies to obtain the needed drugs. Yet, the majority of discussion on Capitol Hill regarding the reauthorization of the RWCA has focused on the ADAP, and very little attention is being paid to the plight of clinics and care providers.

Rising demands, insufficient funding, insufficient staffing, and loss of experienced personnel constitute a recipe for disaster. Increased federal funding is urgently needed to bail out failing clinics and practices and to increase staffing to a level sufficient to meet the needs of the patient population. This includes funding directed to accelerate efforts at early diagnosis and treatment among the population in which the epidemic is growing most rapidly. In addition to showing that earlier treatment results in reduced healthcare cost, our studies at UAB have shown that annual costs decline in every category when there is improvement in CD4+ cell counts. Early diagnosis and timely and effective treatment reduce cost, and likely reduce risk of transmission. And although it makes perfect sense to increase policies of widespread HIV testing to reduce costs of care and reduce risk of HIV transmission, how and where will these newly diagnosed patients receive care?

To my colleagues in HIV/AIDS care: Many of you are in similar positions. Discussion of the reauthorization of RWCA is ongoing right now. Write and call your representatives. Go see them in person, and got a favorable reception. One is listened to; less clear that one is heard. We need to speak with one voice.

To policy makers: The HIV/AIDS epidemic continues. The number of infected patients in the US increases annually and clinics do not have sufficient resources to maintain operations without more direct federal assistance. Much of the attention in RWCA reauthorization appears to be focused on ADAP. Although it is a laudable goal to have this program fully funded and to remove patients from waiting lists, availability of medications means little without personnel and resources to monitor patients, to treat side effects, to provide resistance testing interpretation, to alter drug regimens appropriately, to refer for counseling, to provide counseling, to guide patients through the maze of insurance benefits and claims, and to guide them through the maze of lifelong treatment for an incurable disease. In short, to care for them. Without your attention and help, we will lose clinics, practices, and devoted and knowledgeable personnel, and there will be no one to replace them. Without your attention and help, we will lose health care providers with the required skills, knowledge, and dedication to provide appropriate care to this rapidly growing patient population. And without adequate numbers of such health care providers, we will replace waiting lists with waiting lines and lose patients’ lives.

Dr. Michael S. Saag is Professor of Medicine and Director of the Center For AIDS Research at the University of Alabama at Birmingham. He is also a member of the volunteer Board of Directors of the IAS-USA. The remarks in the Commentary have been adapted in part from an interview with Dr. Saag conducted by Michele Norris for the National Public Radio All Things Considered show that aired on April 12, 2006. (see http://www.npr.org/templates/story/story.php?storyid=5339022)

Copyright 2006, International AIDS Society–USA
Guidelines for Authors and Contributors

The International AIDS Society–USA publishes *Topics in HIV Medicine* as a resource for physicians and other health care practitioners who are actively involved in HIV and AIDS care. The journal is indexed in *Index Medicus/MEDLINE* and is distributed to approximately 12,000 national and international subscribers.

The following guidelines describe the types of articles and contributions published in the journal, outline its policies, and provide instructions for authors. For further information, contact *Topics in HIV Medicine* at topics2006@iasusa.org.

**Categories of Articles**

**Perspectives.** Perspectives articles are summaries of selected talks given at International AIDS Society–USA continuing medical education courses. An International AIDS Society–USA medical writer prepares a summary manuscript from a transcript of the talk. The manuscript is reviewed and edited by the specific course presenter and the journal’s appointed peer reviewers.

**Reviews.** *Topics in HIV Medicine* welcomes original review articles on current issues in HIV and AIDS for consideration. *Topics in HIV Medicine* does not publish original research. Manuscripts should be 3000 to 6000 words (excluding references, tables, and figures) and should include numbered references and a brief introductory abstract of approximately 100 to 200 words. Original, adapted, or reprinted figures and tables may be included and should be cited in the text and accompanied by a brief title. Adapted and reprinted work requires proof of permission obtained from the original publishers and authors. Authors interested in submitting unsolicited manuscripts are encouraged to submit an outline or abstract of the proposed manuscript first; please contact the editor for further information.

**Editorials.** *Topics in HIV Medicine* and its editors invite submission of editorials. Editorials should be approximately 500 to 1500 words (excluding references) and should include numbered references.

**Special Contributions.** A special contribution article often represents the unique contribution (such as a consensus statement) of an author or group of authors and is invited by the editors.

**Stories.** Stories for the “Telling Stories” column share the experiences of those involved in HIV and AIDS care. Stories may be approximately 800 to 3500 words; unsolicited submissions are welcome.

**Commentaries.** Discussion on a current issue in HIV medicine is welcome as a Commentary. Commentaries should be 500 to 1500 words and include numbered references as appropriate. Commentaries may be invited by the Editors; unsolicited submissions are also welcome for consideration.

**Letters to the Editor.** Letters to the editor are welcome and should be sent to the address listed below.

**Special Issues.** *Topics in HIV Medicine* publishes 1 or 2 issues each year with a special focus, such as reports from recent scientific meetings and summaries of special International AIDS Society–USA continuing medical education courses.

**Reprints.** Reprints of papers by expert panels convened by the International AIDS Society–USA are periodically included in *Topics in HIV Medicine*.

**Submission of Manuscripts**

Manuscripts should be submitted via e-mail or PC-compatible floppy disk with a double-spaced hard copy to the address below. Each manuscript author should complete an Authorship Form, which is available online at http://www.iasusa.org/pub or may be obtained by contacting the editor at the address below. Outlines or abstracts of proposed manuscripts are welcome and may be sent via mail or e-mail.

**Editor.** *Topics in HIV Medicine*
International AIDS Society–USA
425 California Street, Suite 1450
San Francisco, CA 94104-2120
E-mail: topics2006@iasusa.org

Receipt of submitted manuscripts will be acknowledged by editorial staff, and submissions will be reviewed by peer reviewers. Acceptance for publication is based on the quality and relevance of the work.

**Copyright**

Copyright to manuscripts published in *Topics in HIV Medicine* is owned by the International AIDS Society–USA. All authors and contributors of manuscripts accepted for publication, with the exception of US federal government employees, must sign a copyright transfer form as a condition of publication.

**Authorship Requirements**

*Topics in HIV Medicine* uses the definition of authorship formulated by the International Committee of Medical Journal Editors and published in its Uniform Requirements for Manuscripts Submitted to Biomedical Journals. This definition states: “Authorship credit should be based only on (1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Conditions 1, 2, and 3 must all be met. Acquisition of funding, the collection of data, or general supervision of the research group, by themselves, do not justify authorship.”

**Financial Disclosure**

It is the policy of the International AIDS Society–USA to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. To that end, all authors and contributors of articles published in *Topics in HIV Medicine* are expected to disclose to readers any significant financial interest or other relationship with any organization having financial interest in the content of the manuscript. Financial interests include employment, consultancy, honorarium, grant/research support, major stock ownership, and membership in a speakers bureau. The complete financial disclosure statements for all authors and contributors are published with the articles.

---

Topics in HIV Medicine is published 4-6 times per year. Please complete this form if you would like to obtain a complimentary subscription or notify the International AIDS Society–USA of a change in address. Subscribers will also receive information about upcoming International AIDS Society–USA continuing medical education courses.

Please mark the appropriate box:

☐ I would like to subscribe to Topics in HIV Medicine. Please send my subscription to the address below.

☐ I am a current subscriber. Please note my change of address below.

IAS–USA ID Number ____________ Please see upper left corner of mailing address as shown in sample.

First Name __________________________ M I __________________________ Last Name __________________________

Degree or License (MD, RN, PA, none, etc) ____________ Title ____________

Institution or Organization __________________________

Institution or Organization __________________________

Specialty / Primary Field of Interest __________________________

Address (please check one) ( Home Address Work Address )

City __________________________ State / Province __________________________

Postal Code __________________________ Country __________________________

Telephone __________________________ Facsimile __________________________

E-mail Address __________________________

For how many HIV-infected patients are you providing care?

What percentage of your total number of patients are HIV-infected? __________ %

Do you work for a commercial company? Yes [ ] No [ ]

(eg, pharmaceutical, diagnostic, medical product, advertising, insurance, investment, communications)

If yes, please indicate company: __________________________

Fax or mail this form to: International AIDS Society–USA
425 California Street, Suite 1450
San Francisco, CA 94104-2120
Fax: (415) 544-9401

FOR INTERNAL USE ONLY

DATE ________________ INITIALS ____________ CHANGES ____________________________________________________________________________
Educational Programs of the International AIDS Society–USA

Established in 1992, the International AIDS Society–USA is a not-for-profit physician education organization. The mission of the International AIDS Society–USA is to improve the treatment, care, and quality of life of persons with HIV and AIDS through balanced, relevant, innovative, and state-of-the-art education and information for physicians who are actively involved in HIV and AIDS care. The organization’s educational activities are particularly intended to bridge clinical research and patient care.

Web-Based CME Conferences – www.iasusa.org/webcast

Improving the Management of HIV Disease: Web-based CME Conference, now in its first year, is a series of free online CME activities based on the successful International AIDS Society–USA regional 1-day advanced-level CME courses on HIV/AIDS-related treatment issues.

System Requirements: Windows:
- Pentium 166 megahertz (MHz) processor
- 32 MB of RAM
- 28.8-kilobits per second (Kbps) modem
- 16-bit sounds card and speakers
- 256-color video card
- Internet Explorer 4.0.1 or Netscape 4.0
- Apple Macintosh System 9 or OS X
- Microsoft IE 5.x
- Windows Media Player7.1 (system 9) or 9 series (OS X)

Cases on the Web - www.iasusa.org/cow

Cases on the Web is an ongoing series of case-based, advanced online CME activities produced by the International AIDS Society–USA. Michael S. Saag, MD, of the University of Alabama at Birmingham, is editor in chief of the series, and Meg D. Newman, MD, of the University of California San Francisco, is co-editor.

CURRENT PRESENTATIONS

Diagnosis and Management of Immune Reconstitution Syndrome in HIV-Infected Patients
Jaime C. Robertson, MD, and Carl J. Fichtenbaum, MD

The Importance of Viral Fitness and Drug Resistance in Chronic and Recent HIV Infection
Mark A. Wainberg, PhD, and Dan Turner, MD

Management of Virologic Failure in Treatment-Experienced Patients
Carlos Zala, MD, and Pedro Cahn, MD, PhD

Management of Tuberculosis in the Context of HIV/AIDS
Pedro Cahn, MD, PhD

2006 CME Courses

Improving the Management of HIV Disease®, now in its 14th year, continues to focus on cutting-edge, scientifically rigorous agendas presented by leading experts in the field. The agendas and schedules for the 2007 CME courses will be available at www.iasusa.org shortly.

9th Annual Ryan White CARE Act Clinical Conference*
Washington, DC (Part of the All Grantees Meeting)
August 28-31, 2006
Marriott Wardman Park Hotel
Chairs: Laura W. Cheever, MD, ScM, Michael S. Saag, MD, and Donna E. Sweet, MD
*Note: Only Ryan White CARE Act grantees may register for this course

New York, NY
October 17, 2006
New York Marriott Marquis
Chairs: Douglas T. Dieterich, MD, and Roy M. Gulick, MD

For information about any of these programs, please contact the International AIDS Society–USA.
Phone: (415) 544-9400  •  Fax: (415) 544-9401  •  E-mail: info2006@iasusa.org  •  Web Site: www.iasusa.org
Visit our Web site at www.iasusa.org for...

- Web Casts of IAS-USA CME courses
- Slides and audio presented by national and international experts in HIV/AIDS care
- Ideal for clinicians who are unable to attend live regional courses
- Learn at your own pace and earn free CME credit
- Also available as Podcasts (audio only format)